Enveda Therapeutics raised a $311 million Series E to expand its AI-driven pipeline, pushing additional programs into human testing and later-stage development. The round, led by Catalio Capital Management, values the company at roughly $2 billion and positions the startup to continue scaling PRISM—its nature-derived discovery platform. Enveda’s update emphasizes three oral candidates in clinical trials, including ENV-294 for atopic dermatitis and ENV-308 for metabolic health and weight maintenance after stopping GLP-1 therapies, along with ENV-6949 targeting TL1A for inflammatory bowel disease. Early clinical signals reported this year were cited as part of the investment narrative. For biotech investors and partners, the funding is a concrete validation of “AI-to-clinic” execution in natural product-inspired discovery—especially when the pipeline already shows human pharmacology and early efficacy signals.